Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children (HU Prevent)
- Conduct a randomized placebo-controlled trial of HU to reduce the CNS complications (abnormal CBFV, SCI and stroke) of SCD
- Determine the safety of study procedures using standardized protocols in toddlers and preschool children with SCD
SCD patients with hemoglobin SS or Sβ0, 9 to 48 months of age, with no history of focal neurologic event, other neurological problems, or currently taking HU.
PI: Dr. Janet Kwiatkowski
SC: Helen Stanley, Jolene Kokroko
Sponsor: National Institutes of Health